1 dicembre, Seminari del DSF: "Synthetic approaches to the development of new Antibody-Drug Conjugates charged with unconventional payloads"

Quando: 
Mercoledì, Dicembre 1, 2021

Mercoledì 1 dicembre appuntamento con i Seminari del DSF: "Synthetic approaches to the development of new Antibody-Drug Conjugates charged with unconventional payloads”, il talk è tenuto da Elena Petricci (UNISI-DBCF).

L'incontro si svolgerà dalle 13:00 alle 13:40, in lingua inglese, in modalità webinar.

Questo il link per collegarsi: meet.google.com/kwe-hhxd-hka

Host del webinar Alberto Minassi (DSF-UPO).

Abstract:

With more than 50 Antibody Drug Conjugates (ADCs) in clinical trials for cancer treatment, the ADC approach opens a new era of chemotherapy. ADCs activity is strictly related to the chemical properties of both linker and payload, while the conjugation methodologies impact their homogeneity. Here we report our experience in the development of novel ADCs that can deliver to human tumors Hystone DeACetylase (HDAC) inhibitors and other payloads (i.e. Smo inhibitors) with low cytotoxicity. Different payloads were prepared using both cleavable and noncleavable linkers and conjugated to Cetuximab and Trastuzumab resulting in ADCs exhibiting unmodified ability to recognize EGFR and efficient internalization into tumor cells. Animal models of human solid tumors showed high anti-tumor efficacy of the conjugates without the toxicity of traditional ADCs charged with highly potent cytotoxic drugs. These new bioconjugates proved to be suitable for targeted epigenetic modulation possibly extending the ADC strategy to therapeutic applications beyond cancer.

Ultimo aggiornamento: 29/11/2021 - 09:52